A Study of Combination Therapy in Patients With Resectable Liver Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAffiliated Hospital of Guangdong Medical University
About this trial
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer. Eligible participants will receive combination therapy prior to surgical intervention. Patients who meet predefined surgical criteria will undergo hepatic resection. Following surgery, additional treatment may be administered according to the investigator's assessment. The primary objective is to evaluate time to treatment failure (TTF). Secondary objectives include evaluation of pathological response, resection outcomes, progression-related outcomes, survival outcomes, and safety.
Eligibility criteria
Qualifiers
1. Voluntarily signed written informed consent.
2. Age ≥18 years; male or female.
3. Histologically, cytologically, or clinically confirmed hepatocellular carcinoma (HCC) according to EASL/AASLD criteria.
4. CNLC stage Ib, IIa, IIb, or IIIa HCC (excluding patients with main portal vein tumor thrombus).
Disqualifiers
1. Intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular carcinoma, fibrolamellar carcinoma, or any other active malignancy within the past 5 years (except HCC).
2. Severe allergy to iodinated contrast agents that prevents HAIC treatment.
3. Planned or prior organ transplantation or allogeneic bone marrow transplantation.
4. Treatment with another investigational drug within 28 days before study treatment.
Trial design
Treatments tested in this trial
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
Treatment groups
68 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov